Trajectories of Neurotoxicity in young Hodgkin lymphoma patients
Official title: Trajectories of Neurotoxicity Among Patients with Adolescent and Young Adult Hodgkin Lymphoma
Funded at University of Rochester · NIH-11432883 · Data updated 2026-11-12
Aging Hodgkin lymphoma patients who are adolescents or young adults may face long-lasting brain and nerve-related side effects from their cancer treatment, and this study aims to map how those problems develop over time.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Rochester NIH-funded |
| Lab location | 1 site (Rochester, United States) |
| Project start | September 1, 2026 |
| Project end | August 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $814,967 |
| NIH project number | 1R37CA316700-01 |
| Project ID | NIH-11432883 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates are adolescents and young adults diagnosed with Hodgkin lymphoma who have completed therapy but may still experience neurotoxic symptoms.
✕Less likely to help
Patients without neurotoxic symptoms or not reachable for follow-up may not directly benefit.
What this research studies
This project follows adolescents and young adults treated for Hodgkin lymphoma to understand how neurotoxic effects like cognitive changes and neuropathy emerge and progress after therapy. It uses self-report data and clinical measures to track symptoms, inflammation, and oxidative stress over time. By focusing on the AYA population, the study hopes to identify patterns that could guide future interventions to protect brain and nerve health.
Why it matters
Potential benefit: If successful, the research could lead to earlier recognition and better management of neurotoxic symptoms in AYAs, improving quality of life and functional outcomes.
How similar studies have gone: Previous studies in long-term survivors suggest a link between neurotoxicity and functional outcomes, supporting the potential of this trajectory study.
Where this research is happening
-
University of Rochester
Rochester, United States Active
Researchers
- Principal investigator: Williams, Annalynn — University of Rochester
- Study coordinator: Williams, Annalynn
Related research
Other NIH-funded projects on the same topics.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Novel combination therapy for non-Hodgkin lymphoma in people and dogs
A new treatment combo using an oncolytic virus and other therapies is being tested to help people with hard-to-treat non-Hodgkin lymphoma, with studies also involving dogs to better understand responses.
-
Combination therapy approach for non-Hodgkin lymphoma (NHL)
A Mayo Clinic team is testing a new combination treatment for non-Hodgkin lymphoma to improve responses in patients and in dogs with similar disease.
-
Multi-antigen T cell therapy for relapsed NHL
A patient-derived T cell therapy called MT-601 targets six tumor-associated antigens to help treat relapsed non-Hodgkin lymphoma after other therapies may have failed.
-
Personalized de‑intensification of therapy for NLP Hodgkin lymphoma
A clinician-scientist at Stanford is developing a patient-centered program to tailor and reduce therapy for nodular lymphocyte-predominant Hodgkin lymphoma using tumor and blood samples.
-
Combining international Hodgkin lymphoma data to understand long-term treatment effects
This project brings together trial and registry data to learn how treatments affect long-term health in adults with Hodgkin lymphoma.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.